8
ALL1
Akums Lifesciences6
Eli Lilly1
Ildong PharmaceuticalYear
8
ALL1
20243
20221
20213
2020DEALS // DEV.
8
ALL1
Deals7
DevelopmentsCountry
8
ALL1
INDIA1
SOUTH KOREA6
U.S.A8
ALL1
Daiichi Sankyo1
Eli Lilly6
InapplicableTherapeutic Area
8
ALL8
NeurologyStudy Phase
8
ALL8
Approved FDFDeal Type
8
ALL1
Collaboration7
InapplicableProduct Type
8
ALL8
Controlled SubstanceDosage Form
8
ALL8
Oral Tablet, Film CoatedLead Product
8
ALL8
LasmiditanTarget
8
ALL8
5-HT1F receptorLead Product(s) : Lasmiditan
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Akums Launches Lasmiditan Tablet to Alleviate Symptoms Associated with Migraine
Details : Reyvow-Generic (lasmiditan hemisuccinate) belongs to the “selective serotonin receptor agonists” class of medications and is specifically designed to alleviate the symptoms associated with migraine.
Product Name : Reyvow-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 01, 2024
Lead Product(s) : Lasmiditan
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lasmiditan
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Ildong’s Migraine Drug Patent Blocks Latecomer’s Market Entry
Details : Reyvow (lasmiditan hemisuccinate) is a serotonin (5-HT) 1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults.
Product Name : Reyvow
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 25, 2022
Lead Product(s) : Lasmiditan
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lasmiditan
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CHMP Recommends Eli Lilly's Migraine Medication Rayvow
Details : Rayvow will be available as 50 mg, 100 mg and 200 mg film-coated tablets. The active substance of Rayvow is lasmiditan, a 5-hydroxytriptamine 1F (5-HT1F) receptor agonist (ATC code: N02CC), effecting a decrease of neuropeptide release and an inhibition o...
Product Name : Reyvow
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 23, 2022
Lead Product(s) : Lasmiditan
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lasmiditan
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MHLW Approves Lilly’s Migrane Drug Reyvow, Amgen’s KRAS Inhibitor and More
Details : Reyvow (lasmiditan hemisuccinate) is a serotonin (5-HT) 1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults.
Product Name : Reyvow
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 21, 2022
Lead Product(s) : Lasmiditan
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lasmiditan
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Daiichi Sankyo
Deal Size : Undisclosed
Deal Type : Collaboration
Eli Lilly Japan, Daiichi Sankyo Ink Pact to Commercialise Migraine Drug
Details : Under the agreement, Eli Lilly Japan will hold authorisation for marketing lasmiditan succinate, similar to the humanized anti-CGRP monoclonal antibody Emgality (galcanezumab), and Daiichi Sankyo will take charge of its distribution and sales after marke...
Product Name : Reyvow
Product Type : Controlled Substance
Upfront Cash : Undisclosed
August 30, 2021
Lead Product(s) : Lasmiditan
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Daiichi Sankyo
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Lasmiditan
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Adults who took REYVOW C-V for their migraine attacks at doses of 100 mg or 200 mg had 3.8 and 4.6 times greater odds, respectively, of achieving pain freedom at 2 hours compared to those taking placebo, according to results from the recently completed P...
Product Name : Reyvow
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 09, 2020
Lead Product(s) : Lasmiditan
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lasmiditan
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Reyvow (lasmiditan hemisuccinate) belongs to the “selective serotonin receptor agonists” class of medications and is specifically designed to alleviate the symptoms associated with migraine headaches.
Product Name : Reyvow
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 10, 2020
Lead Product(s) : Lasmiditan
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lasmiditan
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Reyvow (lasmiditan hemisuccinate) belongs to the “selective serotonin receptor agonists” class of medications and is specifically designed to alleviate the symptoms associated with migraine headaches.
Product Name : Reyvow
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 31, 2020
Lead Product(s) : Lasmiditan
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable